Merck & Co., Inc.’s (MRK) “Outperform” Rating Reiterated at Royal Bank Of Canada

Royal Bank Of Canada restated their outperform rating on shares of Merck & Co., Inc. (NYSE:MRK) in a research note released on Monday morning,Benzinga reports. They currently have a $142.00 target price on the stock.

A number of other brokerages have also weighed in on MRK. Citigroup boosted their price objective on shares of Merck & Co., Inc. from $120.00 to $125.00 and gave the stock a “neutral” rating in a report on Friday, March 20th. Wall Street Zen raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research note on Saturday, March 28th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Merck & Co., Inc. in a report on Monday, December 29th. Cantor Fitzgerald lifted their target price on shares of Merck & Co., Inc. from $116.00 to $120.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 4th. Finally, The Goldman Sachs Group boosted their price target on shares of Merck & Co., Inc. from $92.00 to $120.00 and gave the stock a “buy” rating in a research note on Tuesday, December 2nd. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and seven have given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $127.13.

Merck & Co., Inc. Price Performance

Shares of Merck & Co., Inc. stock opened at $121.06 on Monday. The firm has a market capitalization of $299.31 billion, a PE ratio of 16.63, a price-to-earnings-growth ratio of 2.33 and a beta of 0.27. The company has a current ratio of 1.54, a quick ratio of 1.30 and a debt-to-equity ratio of 0.89. Merck & Co., Inc. has a 12 month low of $73.31 and a 12 month high of $125.14. The business’s 50-day moving average price is $117.24 and its 200-day moving average price is $102.68.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $2.01 by $0.03. The company had revenue of $16.40 billion during the quarter, compared to the consensus estimate of $16.19 billion. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.Merck & Co., Inc.’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.72 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. Sell-side analysts forecast that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 7th. Shareholders of record on Monday, March 16th will be given a $0.85 dividend. The ex-dividend date is Monday, March 16th. This represents a $3.40 annualized dividend and a yield of 2.8%. Merck & Co., Inc.’s payout ratio is presently 46.70%.

Insider Transactions at Merck & Co., Inc.

In related news, EVP Richard R. Deluca sold 37,685 shares of Merck & Co., Inc. stock in a transaction on Friday, February 6th. The shares were sold at an average price of $120.92, for a total value of $4,556,870.20. Following the transaction, the executive vice president directly owned 160,174 shares of the company’s stock, valued at $19,368,240.08. The trade was a 19.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CMO Chirfi Guindo sold 10,000 shares of the company’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $118.41, for a total transaction of $1,184,100.00. Following the sale, the chief marketing officer owned 70,615 shares of the company’s stock, valued at $8,361,522.15. This represents a 12.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 320,176 shares of company stock valued at $38,281,735. Insiders own 0.13% of the company’s stock.

Institutional Investors Weigh In On Merck & Co., Inc.

A number of large investors have recently added to or reduced their stakes in MRK. Kingdom Financial Group LLC. purchased a new stake in shares of Merck & Co., Inc. during the fourth quarter worth about $25,000. Prosperity Bancshares Inc purchased a new position in Merck & Co., Inc. during the 4th quarter valued at about $26,000. Abound Financial LLC purchased a new position in Merck & Co., Inc. during the 4th quarter valued at about $26,000. IFC & Insurance Marketing Inc. purchased a new position in Merck & Co., Inc. during the 4th quarter valued at about $31,000. Finally, High Note Wealth LLC increased its holdings in Merck & Co., Inc. by 58.9% during the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after purchasing an additional 109 shares during the period. Institutional investors own 76.07% of the company’s stock.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Completed acquisition of JSR Life Sciences’ chromatography business broadens Merck’s downstream purification portfolio with next?generation Protein A chromatography, improving its biomanufacturing offering and positioning it to capture more upstream/downstream spend from biologics manufacturers. Merck Completes Acquisition of JSR Life Sciences’ Chromatography Business
• Positive Sentiment: New R&D collaboration with Infinimmune could deliver up to ~$838M in milestones to Merck as it funds discovery of immune cell?directed antibodies — expands early?stage pipeline and de?risks future biologics launches. Infinimmune, Merck enter into antibody discovery pact
• Positive Sentiment: Merck’s recent acquisitions and the Terns buy (noted in coverage) signal management’s push to bolster oncology revenue streams — a strategic move that supports longer?term growth and margin expansion. Merck Just Made a Big Bet on a New Cancer Growth Engine
• Positive Sentiment: Royal Bank of Canada issued an Outperform rating on MRK, which can draw buying interest from institutional investors and supports the stock’s momentum. Merck & Co., Inc. (NYSE:MRK) Earns Outperform Rating from Royal Bank Of Canada
• Positive Sentiment: Latest quarterly results showed an EPS beat and raised FY?2026 EPS guidance (5.000–5.150), supporting the view that core operations and margins remain healthy. Merck & Co., Inc. Stock/Results Summary
• Neutral Sentiment: Coverage pieces highlighting Merck as an “affordable” dividend/defensive stock and inclusion in lists of defensive names may increase retail interest but are unlikely to move fundamentals materially. Why is Merck & Co. (MRK) One of the Best Affordable Stocks to Buy With Good Earnings Growth?
• Neutral Sentiment: Coverage noting an expanded collaboration between Tempus AI and Merck highlights partnerships in data/AI, but the near?term revenue impact for Merck is unclear. Assessing Tempus AI (TEM) Valuation After ALERT Cardiology Trial Results And Expanded Merck Collaboration
• Neutral Sentiment: Macro/market pieces (Barclays’ defensive picks, Blackstone fund closing) provide context for investor flows into healthcare but do not directly change Merck’s fundamentals. Barclays names top 4 defensive stocks to weather global uncertainty
• Negative Sentiment: Short?term price churn has appeared in recent sessions (some intraday dips and lagging vs. the broader market on certain days), reflecting market volatility and rotation risk that could cap near?term upside. Merck (MRK) Dips More Than Broader Market: What You Should Know

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.